Arcellx (ACLX) Stock Price

Arcellx Price

NASDAQ·CLOSED
115.07
​
Market closed

Over the last 3 years Arcellx grew revenue by 7.6% annually, reaching 22.29 M USD. For Arcellx, the net margin of -1,027.3% is up versus -1,053.4% a few years ago. The consensus 12-month price target for Arcellx is 114.24 USD, about 0.7% below where the stock trades today. Of 26 analysts, 23 rate the stock a buy — an overall Buy consensus.

Arcellx stock price

Access this data via the Eulerpool API

Arcellx business model & stock analysis

Arcellx, Inc is a clinical-stage biotechnology company, which provides cell therapy through the development of innovative immunotherapies for patients with cancer and other incurable diseases. The company is headquartered in Gaithersburg, Maryland and currently employs 98 full-time employees. The company went IPO on 2022-02-04. The firm is focused on the development of controllable cell therapies for the treatment of patients with cancer and other incurable diseases. The Company’s lead program is a BCMA-targeting ddCAR product candidate called CART-ddBCMA, which is being evaluated in its pivotal Phase II iMMagine-1 trial in patients with relapsed or refractory multiple myeloma (rrMM). The firm is also developing two clinical-stage ARC-SparX programs in Phase I trials; ACLX-001, which targets BCMA in rrMM, and ACLX-002, which targets CD123 in relapsed or refractory acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (MDS). Outside of multiple myeloma (MM), the Company advances its wholly owned portfolio of clinical-stage, ACLX-002, and preclinical pipeline programs incorporating its D-Domain technology.

Frequently asked questions about Arcellx

Analysts currently set an average price target of 114.60 USD for the Arcellx stock (median: 114.24 USD), implying -0.4 % versus the latest price. The consensus is based on 26 analyst ratings.

26 analysts currently rate the Arcellx stock: 23 recommend buying, 3 holding and 0 selling. For 2026, analysts expect Arcellx to generate revenue of 73.34 M USD and earnings per share of -3.77 USD.

Converted at the current exchange rate, the Arcellx share trades at 102.28 EUR (115.07 USD).

The Arcellx share (ACLX) is listed on 1 stock exchanges, including: NASDAQ (ACLX).

The expected revenue of Arcellx is 73.34 M USD. This figure is based on current financial data and reflects the company's business performance.

The expected profit of Arcellx is -212.17 M USD. The net profit reflects the company's profitability after deducting all expenses.

The price-to-earnings ratio (P/E) of Arcellx is currently -30.54. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the Arcellx stock.

The price-to-sales ratio (P/S) of Arcellx is currently 88.34. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the Arcellx stock.

The Eulerpool Quality Score for Arcellx is 3/10.

The ISIN of Arcellx is US03940C1009. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.

The ticker of Arcellx is ACLX. The ticker symbol is used to trade Arcellx shares on the stock exchange.

Fair ValueTerminal
94.36 USD
Over-/UndervaluationTerminal
Fairly valued
Sector
Industry
Biotechnology
Number of shares
Employees
Revenue per Employee
106,631.58 USD
Revenue growth Ø5 years
EBIT growth Ø5 years
Net Income growth Ø5 years
Website arcellx.com
Currency
USD
Initial public offering
Feb 4, 2022
ISIN
US03940C1009
Cusip
03940C100
Market capitalization
6.65 B USDMid Cap
52-Week Range
Revenue growth (10Y) > 5%
Revenue growth (3Y) > 5 %
EBIT growth (10Y) > 5%
EBIT growth (3Y) > 5 %
Net debt < 4x EBIT
Profitable since 10Y+
EBIT Drawdown (10Y) < 50%
Return on Equity (ROE) > 15%
ROCE > 15%
Return Expectation > 10%
PEG
—
P/E ratio
P/Ee 2026
-30.54
P/Ee 2027
-65.66
P/Ee 2028
292.50
P/Ee 2029
29.71
P/Ee 2030
15.50
P/Se
88.34
EV/EBIT
—
P/B Ratio
16.54
ROE (Return on Equity)
ROA (Return on Assets)
ROCE (Return on Capital Employed)
ROIC (Return on Invested Capital)
-55.85 %
Gross Margin
70.04 %
EBIT Margin
-1,135.61 %
Net Margin
-1,027.25 %
EPS (Earnings Per Share)
-4.07 USD
Net Debt / EBIT
0.29
Debt/Equity
0.02
Last updated Oct 5, 2026, 11:55 AM

Arcellx Peer Group

Arcellx Ticker

NASDAQ · ACLX

Arcellx FIGI

ACLX:US · BBG00QHJM4S9ACLX:UA · BBG014L7WVJ7ACLX:UC · BBG014L7WVK5ACLX:UN · BBG014L7WVM3ACLX:UP · BBG014L7WVN2ACLX:UB · BBG014L7WVQ9ACLX:UM · BBG014L7WVS7ACLX:UX · BBG014L7WVT6ACLX:UD · BBG014L7WVZ9ACLX:UW · BBG014L7WW14ACLX:UF · BBG014L7WW23ACLX:VY · BBG014L7WW32

All fundamentals and in-depth analysis of Arcellx

Our stock analysis for Arcellx stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Arcellx. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.